Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics gets approval for PQ Grass trial

Allergy Therapeutics has received approval for a phase II clinical trial of investigating the dosing of PQ Grass, an ultra-sho...

Approval for PQ Grass Phase II trial

RNS Number: 9660Q Allergy Therapeutics PLC 18 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Approval of clinical trial application for PQ Grass Phase II trial - Trial aimed at determining optimal dose of an MPL-adjuvanted, modified grass allergy vaccine - 18 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integra...

Allergy Therapeutics expands R&D and clinical team

Allergy Therapeutics has announced new senior appointments and expansion of the R&D and clinical team in line with th...

Expansion of Clinical Development and R&D teams

RNS Number: 2846Q Allergy Therapeutics PLC 11 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Expansion of Clinical Development and R&D teams - Key appointments reflect Group's commitment to EU and US strategy for product development - 11 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated special...

All News

DateHeadlineSource
27-06-16Findings from mEEC dose range finding study G204RNS
13-06-16Allergy Therapeutics' satellite symposium at EAACIStockMarketWire
13-06-16Allergy hosts Satellite Symposium at EAACIRNS
10-06-16Appointment of Finance DirectorRNS
18-05-16Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are a dying breedMotley Fool
09-05-16Allergy Therapeutics positive data from PQBirch204 studyStockMarketWire
09-05-16Positive Phase II DataRNS
21-04-16This list of shares keeps outperformingInteractive Investor
23-03-16Allergy Therapeutics options exercised StockMarketWire
23-03-16Issue of equity in respect of options exerciseRNS
17-03-16Allergy Therapeutics FD resigns StockMarketWire
17-03-16Board ChangeRNS
14-03-16Allergy Therapeutics grants options under LTIP StockMarketWire
11-03-16Grant of Options under Long Term Incentive PlanRNS
10-03-16Broker Forecast - Panmure Gordon issues a broker note on Allergy Therapeutics PLCStockMarketWire
08-03-16Interim Results for the six months ended 31/12/15RNS
24-02-16Hardman & Co Research Report: Development ProgressRNS
23-02-16Allergy Therapeutics schedules interim resultsStockMarketWire
23-02-16Notice of Interim ResultsRNS
18-02-16Allergy Therapeutics completes patient enrolmentStockMarketWire
18-02-16Patient enrolment completed in US Phase IIb studyRNS
13-01-16Allergy Therapeutics sees double digit growth StockMarketWire
13-01-16Trading UpdateRNS
07-12-15Allergy Therapeutics initiates US phase II studyStockMarketWire
07-12-15US Phase II study for GrassMATAMPL initiatedRNS
02-12-15Holding(s) in CompanyRNS
30-11-15Allergy Therapeutics completes patient enrolmentStockMarketWire
30-11-15PQBirch204 Phase II study updateRNS
27-11-15Holding(s) in CompanyRNS
26-11-15Allergy Therapeutics grants optionsStockMarketWire
25-11-15Grant of Options under Long Term Incentive PlanRNS
18-11-15Result of AGMRNS
17-11-15Results of PlacingRNS
17-11-15Allergy Therapeutics to raise up to £12mStockMarketWire
17-11-15Proposed placing to raise up to £12 millionRNS
17-11-15Trading UpdateRNS
04-11-15Allergy Therapeutics to present at World Vaccine Congress StockMarketWire
04-11-15World Vaccine Congress PresentationRNS
21-10-15Hardman research report on Allergy TherapeuticsStockMarketWire
21-10-15Hardman & Co issues research reportRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory